New psychopharmacotherapy dilemmas associated with COVID-19 – case report

Jolanta Kucharska-Mazur; Jędrzej Stańczak; Jerzy Samochowiec

Pełna treść

2/2020 vol. 36

Opis przypadku

Nowe dylematy psychofarmakoterapii związane z COVID-19 – opis przypadku

Jolanta Kucharska-Mazur ¹

,

Jędrzej Stańczak ¹

,

Jerzy Samochowiec ¹

Department of Psychiatry, Pomeranian Medical University in Szczecin

Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 149–153

Data publikacji online: 2021/12/06

Plik artykułu

06R_IPiN_FARM_2020-2C.pdf

AMA

Kucharska-Mazur J, Stańczak J, Samochowiec J. New psychopharmacotherapy dilemmas associated with COVID-19 – case report. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2020;36(2):149-153.

APA

Kucharska-Mazur, J., Stańczak, J., & Samochowiec, J. (2020). New psychopharmacotherapy dilemmas associated with COVID-19 – case report. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 36(2), 149-153.

Chicago

Kucharska-Mazur, Jolanta, Jędrzej Stańczak, and Jerzy Samochowiec. 2020. "New psychopharmacotherapy dilemmas associated with COVID-19 – case report". Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii 36 (2): 149-153.

Harvard

Kucharska-Mazur, J., Stańczak, J., and Samochowiec, J. (2020). New psychopharmacotherapy dilemmas associated with COVID-19 – case report. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 36(2), pp.149-153.

MLA

Kucharska-Mazur, Jolanta et al. "New psychopharmacotherapy dilemmas associated with COVID-19 – case report." Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, vol. 36, no. 2, 2020, pp. 149-153.

Vancouver

Kucharska-Mazur J, Stańczak J, Samochowiec J. New psychopharmacotherapy dilemmas associated with COVID-19 – case report. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2020;36(2):149-153.

Arechin, ChPL, http://www.urpl.gov.pl/sites/default/files/Are chin%20Charakterystyka%20Produktu%20Leczniczego.pdf.
Detailed recommendations for interactions with experimen tal COVID-19 therapies. https://www.covid19-druginterac tions.org/, University of Liverpool.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 as sociated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16; 14(1): 72–73. Doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J, Skipitaris N, Mountantonakis S, Epstein LM. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol. 2020 Apr 29. doi: 10.1161/CIRCEP.120.008662.
Touret F, Lamballerie X. Of chloroquine and COVID-19, Antiviral Res. 2020 May; 177: 104762. Doi: 10.1016/j.anti viral.2020.104762.
Uvais NA. The Risks of Prescribing Hyodroxychloroquine in COVID-19-Infected Patients With Schizophrenia. Prim Care Companion CNS Disord. 2020 Apr 30;22(3). pii: 20com02635. Doi: 10.4088/PCC.20com02635

ZGŁASZANIE PRAC

Udostępnij

Zintergrowane z

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications